ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OCS
GYRE (43) CTMX (14) ARVN (22) CBIO (29) ⌘ Pro Terminal →

Oculis Holding AG (OCS) — RQD Stock Rating Cockpit

$7.71 -6.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.60

Oculis Holding AG (OCS) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $508.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OCS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Oculis Holding AG (NASDAQ: OCS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $7.71 (-6.66% 1D, market cap $508.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OCS ranks #308 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OCS compare to GYRE and CTMX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OCS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E 72.3x, ROIC 25.4%, cap $507.9M) and CTMX (CytomX Therapeutics Inc.) posts a E grade (14/100 RQD, P/E N/A, ROIC -20.5%, cap $509.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OCS?
▼

For Oculis Holding AG (OCS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #308 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.60 (-1.39%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (5)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.9% Base Target
$36 Bull$7 Base$6 Bear
📬 FREE OCS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OCS)Realized 20D OHLCV Swing Band: ±11.9%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY OCS SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($14.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$7.62-1.7% Next Q
Q2 (-2Q)
42
Grade D$7.49+4.5% Next Q
Q3 (-1Q)
44
Grade D$7.83-1.5% Next Q
Current
47
Grade D$7.71-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OCS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OCS currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.55) and Max Pain ($8.10) forces dealer call-delta covering toward $36.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OCS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OCS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
45.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $7$7.71H: $34
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on OCS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like OCS
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OCS)

  • ✓Walkthrough of OCS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OCS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -72.72%⚡ TESTING RESISTANCE
2026-11-03O $8.24H $8.26L $7.71C $7.71VOL 309.7K
RES: $8.65SUP: $6.15SMA50: $9.55SMA200: $18.66
$36.39$28.45$20.52$12.58$4.65RES $8.65SUP $6.15$7.712026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OCS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OCS Butterfly Map → + Track OCS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OCS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OCS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OCS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OCS)

Health Care Rank #308 of 1015 ⚔️ GYRE vs OCS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OCS vs. GYRE, CTMX, ARVN, CBIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Oculis Holding AG (OCS) ranks #308 by composite RQD confidence (47/100, grade D) and #437 by equity capitalization ($508.7M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. OCS currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OCS ACTIVE
Oculis Holding AG
D 47/100 — — — -6.66% $508.7M Benchmark Subject
GYRE
Gyre Therapeutics Inc.
D- 43/100 72.3x 95.4% 25.4% +3.84% $507.9M /gyre-vs-ocs →
CTMX
CytomX Therapeutics Inc.
E 14/100 — — -20.5% -4.70% $509.9M /ctmx-vs-ocs →
ARVN
Arvinas Inc.
E 22/100 — — -32.1% -4.33% $513.9M /arvn-vs-ocs →
CBIO
Crescent Biopharma Inc.
E 29/100 — — -35.0% -4.23% $500.7M /cbio-vs-ocs →

2. OCS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Oculis Holding AG (OCS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $508.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. OCS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Oculis Holding AG (NASDAQ: OCS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $7.71 (-6.66% 1D, market cap $508.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OCS ranks #308 in composite RQD confidence.

How does OCS compare to GYRE and CTMX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OCS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E 72.3x, ROIC 25.4%, cap $507.9M) and CTMX (CytomX Therapeutics Inc.) posts a E grade (14/100 RQD, P/E N/A, ROIC -20.5%, cap $509.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OCS?

For Oculis Holding AG (OCS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #308 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OCS trading relative to its 50-day, 200-day, and 52-week technical levels?

OCS last traded at $7.71 (-6.66% on volume of 246,363 shares), positioning the stock -19.27% below its 50-day simple moving average ($9.55) and -58.68% below its 200-day simple moving average ($18.66). Across its 52-week range of $7.11 to $34.47, OCS sits at the 2.2% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($6.79 to $8.63).

Direct Sub-Reports: OCS RQD Cockpit OCS 12M Forecast OCS Earnings & Move OCS Dividends & DRIP OCS Insiders & 13F OCS Whale Options OCS Profit Sankey OCS News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

OCS — Oculis Holding AG: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Oculis Holding AG (OCS) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $7.71 (-6.66% 1D, market capitalization $508.7M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Oculis Holding AG (OCS) is listed on NASDAQ and classified under the Health Care sector, in the Biotechnology: Pharmaceutical Preparations industry. The profile lists a market capitalization of $0.5B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $7.11 – $34.47 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or bottlenecks are identified in the source data. Sector classification is Health Care and industry is Biotechnology: Pharmaceutical Preparations. Beyond this classification, no ripple effects can be drawn from the source.

  • Key Question #1: Can OCS sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $34.47 52-week high?
  • Key Question #3: How sensitive is OCS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OCS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Oculis Holding AG (OCS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OCS Debate Forum (3) ↓
🔴 RISK WATCH Benzinga • 12d ago
Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective, complementary biological

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OCS Bull vs. Bear Conversation Board — What's Your Call at $7.71?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OCS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OCS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $10.24 (+24.0%)
📌 Pinned Debate

The balance sheet metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) are the strongest pillar at 13/20.

Here is why I am bullish on OCS here at $8.26: The balance sheet metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) are the strongest pillar at 13/20.. Compare OCS's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $7.85 are getting bought.

SectorRotator 🐂 BULL

@DeltaGamma_99 Agree on the RQD 47/100 quality, though with 1.0 beta I'm scaling in with half-size at $8.26 and keeping dry powder in case we test $7.68.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $6.61 (-20.0%)
Spot @ $8.26

Zero ROIC and zero FCF yield, combined with a 5/20 whale flow score and a D-grade distribution warning, show weak cash returns and inst

Careful chasing OCS at $8.26. Zero ROIC and zero FCF yield, combined with a 5/20 whale flow score and a D-grade distribution warning, show weak cash returns and institutional selling pressure.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $6.61 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%